Coya's ALS study overshoots recruitment target ahead of spring 2027 data readout
Coya Therapeutics has signed up 137 patients to its COYA 302 late-stage ALS programme, and says its cash should last beyond the first results.
Coya Therapeutics has closed recruitment to ALSTARS, the combined Phase 2/3 study of its ALS candidate COYA 302, with 137 patients enrolled against a plan for 120. The company disclosed the milestone alongside its third-quarter 2026 results.
The commercial clock now centres on the first results. Coya expects to release 24-week topline data in early Q2 2027, the point at which the value of its lead programme is likely to be tested. The company also says it plans to offer participants an open-label extension.
The financial picture is that of a pre-revenue developer. Coya posted a net loss of $10.6 million for the quarter and held $35.8 million in cash at 30 September 2026. Management projects that this will fund operations into the second half of 2027, which would cover the period through the expected readout.
The material available for this report was limited to the company's own summary. Details of the trial design, endpoints and the extension study were not included, and the company has not set out how it would finance activity beyond the projected runway.
Why it matters
- Early Q2 2027 is the guided date for ALSTARS topline data, a milestone for anyone tracking the ALS pipeline.
- Recruiting 137 patients rather than 120 gives the study a larger dataset than first planned.
- An open-label extension, if run, would be expected to add longer-term safety information.
- Cash of $35.8 million is guided to last into the second half of 2027, but no funding plans beyond that have been disclosed.
Company's press release (SEC filing): Coya Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
